Soluble guanylyl cyclase as a therapeutic target in chronic obstructive pulmonary disease (COPD) by Constantinos Glynos et al.
POSTER PRESENTATION Open Access
Soluble guanylyl cyclase as a therapeutic target
in chronic obstructive pulmonary disease (COPD)
Constantinos Glynos1,2*, Dimitris Toumpanakis1, Zongmin Zhou1, Peter Brouckaert3,4, Theodoros Vassilakopoulos1,
Andreas Papapetropoulos2
From 6th International Conference on cGMP: Generators, Effectors and Therapeutic Implications
Erfurt, Germany. 28-30 June 2013
Background
Resistive breathing (RB) due to airflow limitation is the
pathophysiologic hallmark of chronic obstructive pul-
monary disease (COPD). Nitric oxide (NO) is a physio-
logical regulator of smooth muscle tone that acts
through activation of soluble guanylyl cyclase (sGC). We
hypothesized that increased smooth muscle tone limit-
ing airflow in COPD could result from reduced sGC.
Herein, we investigated the expression and downstream
signalling of sGC in RB.
Materials and methods
C57BL/6 mice were subjected to RB by restricting tra-
cheal diameter by 50% using a nylon band. Animals
were divided into the following groups: 1. Wild-type
sham operated mice. 2. Wild-type mice subjected to tra-
cheal banding (TB). 3. sGC-a1 -/- sham operated mice.
4. sGC-a1 -/- TB mice. 5. Wild-type sham operated
mice treated with inhaled sGC inhibitor, (ODQ; 20mg/
Kg). 6. Wild-type TB mice treated with inhaled sGC
inhibitor, (ODQ; 20mg/Kg). 7. Wild-type sham operated
mice treated with the sGC activator, BAY 58-2667
(10µg/Kg; ip). 8. Wild-type TB mice treated with sGC
activator, BAY 58-2667(10µg/Kg; ip).
Results
Mice subjected to TB, exhibited a significant increase in
BALF cellularity and protein content, consistent with the
presence of acute inflammation. TB resulted in an increase
in tissue elasticity and airway resistance and in a down-
ward shift of the pressure-volume curve. TB reduced the
expression of both a1 and b1 subunits of sGC, at mRNA
and protein level in the lung. A pronounced inflammatory
response was observed after ODQ administration or by
knocking out the sGC a1 locus. Pharmacological activa-
tion of sGC, using BAY 58-2667, 30 min before or 24 hrs
after TB, reversed the effects of RB in the lung.
Conclusions
Our results indicate that sGC activation protects TB mice
by reducing inflammation and improving lung mechanics
and raise the possibility that sGC could potentially be used
to ameliorate lung function in COPD patients.
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